Testosterone and the aging male
Abstract
The number and magnitude of studies involving testosterone-supplementation therapy in older men are limited. In addition, many studies to date have not been blinded or controlled, were reported in abstract form only, and had involved a variety of androgen-replacement regimens and outcomes measurements. Nonetheless, an overview of the data suggests there is real potential for supplementation therapy to improve bone mass and muscle mass and strength in this age group. Affects on mood, sexual function, and cognition are less clear but may be meaningful in certain men. Questions still remain, however, on the magnitude and longevity of the beneficial effects of testosterone supplementation in the older man and whether only certain subgroups of men would truly benefit from therapy. More importantly, the long-term risks of androgen therapy in this age group really are not known, especially in the areas of cardiovascular disease and prostate diseases. Presently, men who use androgen-supplementation therapy for age-related "testosterone deficiency" should consider this as a gamble.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.